Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | DNMT3B | Q9UBC3 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HTR7 | P34969 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31692801 | 0.81 | HNF4A (0.44) | NPC1RAB9AALDH1A1MEN1KMT2A | |
| SCHEMBL31692820 | 0.81 | HNF4A (0.50) | NPC1RAB9AALDH1A1MAPK1MEN1 | |
| SCHEMBL20328777 | 0.80 | TSHR (0.53) | ALDH1A1KMT2AKDM4EMAPTHTT | |
| SCHEMBL10656431 | 0.80 | ALDH1A1 (0.47) | NPC1RAB9AALDH1A1MEN1KMT2A | |
| SCHEMBL22522164 | 0.79 | KMT2A (0.37) | NPC1RAB9ADNMT3BALDH1A1MAPK1 | |
| SCHEMBL29210435 | 0.79 | MAPT (0.47) | ALDH1A1MEN1KMT2AKDM4EMAPT | |
| SCHEMBL31056786 | 0.78 | VCAM1 (0.50) | NPC1RAB9AALDH1A1MEN1KMT2A | |
| SCHEMBL20476341 | 0.78 | MERTK (0.48) | NPC1RAB9AMAPK1MEN1KMT2A | |
| SCHEMBL10657383 | 0.78 | PRMT5 (0.37) | NPC1RAB9ADNMT3BALDH1A1MEN1 | |
| SCHEMBL31692827 | 0.78 | ALDH1A1 (0.41) | NPC1RAB9AALDH1A1MAPK1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10968198-B2 | Biaryltriazole inhibitors of macrophage migration inhibitory factor | YALE UNIVERSITY (US) | 2021-04-06 | — | — | US | disclosed |
| US-10968198-B2 | Biaryltriazole inhibitors of macrophage migration inhibitory factor | YALE UNIVERSITY (US) | 2021-04-06 | — | — | US | disclosed |
| EP-3267794-B1 | BIARYLTRIAZOLE INHIBITORS OF MACROPHAGE MIGRATION INHIBITORY FACTOR | UNIV YALE (US) | 2020-09-09 | — | — | EP | disclosed |
| US-20190276425-A1 | BIARYLTRIAZOLE INHIBITORS OF MACROPHAGE MIGRATION INHIBITORY FACTOR | UNIV YALE (US) | 2019-09-12 | — | — | US | disclosed |
| US-20190276425-A1 | BIARYLTRIAZOLE INHIBITORS OF MACROPHAGE MIGRATION INHIBITORY FACTOR | UNIV YALE (US) | 2019-09-12 | — | — | US | disclosed |
| US-10336721-B2 | Biaryltriazole inhibitors of macrophage migration inhibitory factor | YALE UNIVERSITY (US) | 2019-07-02 | — | — | US | disclosed |
| US-10336721-B2 | Biaryltriazole inhibitors of macrophage migration inhibitory factor | YALE UNIVERSITY (US) | 2019-07-02 | — | — | US | disclosed |
| US-10081646-B2 | Heterobicyclic sphingosine 1-phosphate analogs | BIOGEN MA INC. (US) | 2018-09-25 | — | — | US | disclosed |
| US-20180179176-A1 | BIARYLTRIAZOLE INHIBITORS OF MACROPHAGE MIGRATION INHIBITORY FACTOR | UNIV YALE (US) | 2018-06-28 | — | — | US | disclosed |
| US-20180179176-A1 | BIARYLTRIAZOLE INHIBITORS OF MACROPHAGE MIGRATION INHIBITORY FACTOR | UNIV YALE (US) | 2018-06-28 | — | — | US | disclosed |
| US-7691866-B2 | 2,6-disubstituted quinazolines, quinoxalines, quinolines and isoquinolines and methods of their use as inhibitors of Raf kinase | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2010-04-06 | — | — | US | disclosed |
| US-7691866-B2 | 2,6-disubstituted quinazolines, quinoxalines, quinolines and isoquinolines and methods of their use as inhibitors of Raf kinase | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2010-04-06 | — | — | US | disclosed |
| US-20090317359-A1 | 2,6-DISUBSTITUTED QUINAZOLINES, QUINOXALINES, QUINOLINES AND ISOQUINOLINES AND METHODS OF THEIR USE AS INHIBITORS OF RAF KINASE | NOVARTIS VACCINES AND DIAGNOSTICS INC. (US) | 2009-12-24 | — | — | US | disclosed |
| US-20090317359-A1 | 2,6-DISUBSTITUTED QUINAZOLINES, QUINOXALINES, QUINOLINES AND ISOQUINOLINES AND METHODS OF THEIR USE AS INHIBITORS OF RAF KINASE | NOVARTIS VACCINES AND DIAGNOSTICS INC. (US) | 2009-12-24 | — | — | US | disclosed |
| EP-1680122-A1 | 2,6-DISUBSTITUTED QUINAZOLINES, QUINOXALINES, QUINOLINES AND ISOQUINOLINES AS INHIBITORS OF RAF KINASE FOR THE TREATMENT OF CANCER | CHIRON CORPORATION (US) | 2006-07-19 | — | — | EP | disclosed |
| WO-2005037285-A1 | 2,6-DISUBSTITUTED QUINAZOLINES, QUINOXALINES, QUINOLINES AND ISOQUINOLINES AS INHIBITORS OF RAF KINASE FOR TREATMENT OF CANCER | CHIRON CORPORATION (US) | 2005-04-28 | — | — | WO | disclosed |
| US-20050085482-A1 | 2,6-Disubstituted quinazolines, quinoxalines, quinolines and isoquinolines and methods of their use as inhibitors of RAF kinase | CHIRON CORPORATION (US) | 2005-04-21 | — | — | US | disclosed |
| EP-0868180-A4 | ENDOTHELIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 1999-08-04 | — | — | EP | disclosed |
| EP-0868180-A1 | ENDOTHELIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-10-07 | — | — | EP | disclosed |
| WO-1997022341-A1 | ENDOTHELIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050085482-A1 | 2,6-Disubstituted quinazolines, quinoxalines, quinolines and isoquinolines and methods of their use as inhibitors of RAF kinase | RAF1, BRAF, ARAF | NPC1 4115/4885RAB9A 742/4885DNMT3B 4080/4885 |
| US-10968198-B2 | Biaryltriazole inhibitors of macrophage migration inhibitory factor | MIF, MMP12, CSF1R | NPC1 751/4885RAB9A 3211/4885DNMT3B 3857/4885 |
| US-10336721-B2 | Biaryltriazole inhibitors of macrophage migration inhibitory factor | MIF, MMP12, CSF1R | NPC1 751/4885RAB9A 3211/4885DNMT3B 3857/4885 |
| US-20090317359-A1 | 2,6-DISUBSTITUTED QUINAZOLINES, QUINOXALINES, QUINOLINES AND ISOQUINOLINES AND METHODS OF THEIR USE AS INHIBITORS OF RAF KINASE | RAF1, BRAF, ARAF | NPC1 4115/4885RAB9A 742/4885DNMT3B 4080/4885 |
| US-20180179176-A1 | BIARYLTRIAZOLE INHIBITORS OF MACROPHAGE MIGRATION INHIBITORY FACTOR | MIF, MMP12, CSF1R | NPC1 751/4885RAB9A 3211/4885DNMT3B 3857/4885 |
| US-20190276425-A1 | BIARYLTRIAZOLE INHIBITORS OF MACROPHAGE MIGRATION INHIBITORY FACTOR | MIF, MMP12, CSF1R | NPC1 751/4885RAB9A 3211/4885DNMT3B 3857/4885 |
| US-10081646-B2 | Heterobicyclic sphingosine 1-phosphate analogs | S1PR1, S1PR2, S1PR4 | NPC1 592/4885RAB9A 2500/4885DNMT3B 4324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.